SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP), a commercial-stage specialty pharmaceutical company, announced the launch and shipment of its pre-filled epinephrine syringe (PFS) (Epinephrine Injection USP 1:1000) to fulfill its initial orders. Epinephrine is utilized for the treatment of extreme acute allergic reactions (anaphylaxis). The epinephrine market is segmented into four different types of allergies, the most common being food and insect venom. Based on initial orders, unit sales projections for the Epi PFS, and anticipated expenses, Adamis’ management predicts the company will reach bottom-line profitability within the first 12 months after the date of launch. Rick Aloi, the President of Adamis Labs, stated, “I believe our pre-filled epinephrine syringe is a low cost, reliable alternative to existing product offerings. We think that with this niche play we will quickly gain sales traction within the $200M epinephrine syringe market.“ Mr. Aloi is knowledgeable concerning the epinephrine market, having played a major role in launching the EpiPen® while Director of Sales for Center Laboratories.
